

**FDA Staff Manual Guides, Volume I – Organizations and Functions**

**Department of Health and Human Services**

**Food and Drug Administration**

**Center for Drugs Evaluation and Research**

**Office of Generic Drugs**

**Office of Bioequivalence**

**Division of Bioequivalence III**

Effective Date: October 9, 2020


**1. Division of Bioequivalence III (DCDMBC).**

- A. Evaluates in vivo and in vitro bioequivalence data and protocols in Abbreviated New Drug Applications (ANDAs) and their supplements and amendments as per the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments), section 505(j) of the Federal Food, Drug, and Cosmetic Act.
- B. Recommends for approval, disapproval, or new bioequivalence studies for ANDAs and/or protocols for all equivalence studies for generic drug products.
- C. Identifies potential bioequivalence problems and provides guidance for conducting bioequivalence studies for all dosage forms as covered in 21 CFR 320.24.
- D. Reviews and evaluates drug disposition data and specialized drug delivery systems to assure bioequivalence of drug products.
- E. Develops new methods, reviews and evaluates pharmacokinetic, pharmacodynamic and in vitro product performance data to assure bioequivalence of drug products. Also provides subject matter expertise on bioequivalence studies to be recommended within product-specific guidances.

**2. Authority and Effective Date.**

The functional statements for the Division of Bioequivalence III were approved by the Commissioner of Food and Drugs on September 8, 2020, and effective on October 9, 2020.

**Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Bioequivalence  
Division of Bioequivalence III**



**Staff Manual Guide 1292.13**  
**Organizations and Functions**  
**Effective Date: December 14, 2018**

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Office of Bioequivalence, Division of Bioequivalence III organization structure depicting all the organizational structures reporting to the Director:

Division of Bioequivalence III (DCDMBC)